
-
BioCryst Pharmaceuticals Inc. NASDAQ:BCRX BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO™ (berotralstat) is approved in the United States and Japan for the prevention of HAE attacks in adults and pediatric patients 12 years and older, and under regulatory review for approval in the European Union and United Kingdom. BioCryst has several ongoing development programs including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for Marburg virus disease and Yellow Fever. RAPIVAB® (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea. Post-marketing commitments for RAPIVAB are ongoing.
Location: 4505 Emperor Blvd Ste 200, North Carolina, 27703-8457, US | Website: www.biocryst.com | Industry: Biological Product (except Diagnostic) Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
2.052B
Cash
320.8M
Avg Qtr Burn
-13.01M
Short % of Float
10.14%
Insider Ownership
1.41%
Institutional Own.
81.17%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Rapivab (Peramivir) Details Influenza, Acute lymphoblastic leukemia, Leukemia | Approved Quarterly sales | |
Orladeyo (Berotralstat) Details Rare diseases, Rare genetic disease, Hereditary angioedema | Approved Quarterly sales | |
BCX17725 Details Netherton syndrome | Phase 1 Data readout | |
Galidesivir (BCX4430) Details COVID-19 | Failed Discontinued | |
BCX9930 Details Paroxysmal nocturnal hemoglobinuria | Failed Discontinued | |
BCX9250 Details Fibrodysplasia ossificans progressiva | Failed Discontinued | |
BCX10013 Details Complement mediated diseases, Paroxysmal nocturnal hemoglobinuria | Failed Discontinued |